ALK and non-small cell lung carcinoma: Of the two fusion types, the EML4-ALK fusion was the same as the most commonly detected variant in NSCLC, [19] where the EML4-ALK fusion is a strong predictive factor for the efficacy of ALK inhibitors [13, 21, 22].